Phaseline

Companies › Beijing InnoCare Pharma Tech

Beijing InnoCare Pharma Tech: clinical trials, targets and expected readouts

11 active drug programs in 60 registered trials: 43 Phase 2, 9 Phase 1, 6 Phase 3, 2 Phase 4; Oncology, Other, Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ICP-332
Spleen tyrosine kinase (SYK) inhibitor
FYNPhase 3Atopic Dermatitis; Prurigo Nodularis (PN); Plaque Psoriasis; Chronic Spontaneous Urticaria (CSU) …Nov 2026
ICP-488–Phase 3Plaque Psoriasis Patients; Cutaneous Lupus Erythematosus (CLE)Feb 2027
Lenalidomide
CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3DLBCLApr 2027
Orelabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsed/Refractory Marginal Zone Lymphoma; Hematologic Malignancies; Part 1:r/r B-cell Malignancies; OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma …Aug 2028
ICP-192
FGFR2 inhibitor
FGFR2Phase 2Intrahepatic Cholangiocarcinoma (ICC)Dec 2026
ICP-248
BTK inhibitor
–Phase 2Relapsed or Refractory Mantle Cell Lymphoma (MCL); Hematologic Malignancies; Hematological Malignancies; Acute Myelogenous LeukemiaJun 2027
CM355–Phase 1HematomaDec 2026
ICP-723–Phase 1Advanced Solid Tumors Harboring NTRK Fusion; Solid TumorsDec 2027
ICP-B208–Phase 1Advanced Solid TumorDec 2030
CM369–Phase 1Advanced Solid Tumors and Hematologic Malignancies–
ICP-538–Phase 1Health Services Research–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05728658ICP-248Phase 1Hematological MalignanciesOncologyAug 2025
NCT05690581CM369Phase 1Advanced Solid Tumors and Hematologic MalignanciesOncologyOct 2025
NCT04014205OrelabrutinibPhase 1Part 1:r/r B-cell MalignanciesOncologyJun 2026
NCT07535099ICP-538Phase 1Health Services ResearchOtherSep 2026
NCT06775860ICP-332Phase 3Atopic DermatitisImmunologyNov 2026
NCT06701357OrelabrutinibPhase 2DLBCLOncologyDec 2026
NCT05678270ICP-192Phase 2Intrahepatic Cholangiocarcinoma (ICC)OncologyDec 2026
NCT05209620OrelabrutinibPhase 2Central Nervous System LymphomaOncologyDec 2026
NCT05210868CM355Phase 1HematomaOtherDec 2026
NCT05933967OrelabrutinibPhase 2The First Affiliated Hospital of Nanchang UniversityOtherDec 2026
NCT06134284OrelabrutinibPhase 4OR Regimen for Relapsed/Refractory Marginal Zone LymphomaOncologyDec 2026
NCT04961515OrelabrutinibPhase 2Primary Central Nervous System Hodgkin LymphomaOncologyDec 2026
NCT06842199ICP-488Phase 3Plaque Psoriasis PatientsImmunologyFeb 2027
NCT07453368OrelabrutinibPhase 2Autoimmune Hemolytic Anemia (AIHA)HematologyMar 2027
NCT06647940OrelabrutinibPhase 2Diffuse Large B Cell Lymphoma (DLBCL)OncologyMar 2027
NCT07236099ICP-332Phase 2Prurigo Nodularis (PN)ImmunologyMar 2027
NCT07440537ICP-488Phase 2Cutaneous Lupus Erythematosus (CLE)ImmunologyMar 2027
NCT07559331OrelabrutinibPhase 3Primary Immune Thrombocytopenia (ITP)HematologyApr 2027
NCT05552937LenalidomidePhase 2DLBCLOncologyApr 2027
NCT07251998ICP-332Phase 2Plaque PsoriasisImmunologyMay 2027
NCT06656494ICP-248Phase 1Acute Myelogenous LeukemiaOncologyJun 2027
NCT06513234OrelabrutinibPhase 2Marginal Zone LymphomaOncologyJun 2027
NCT07680933OrelabrutinibPhase 2DLBCL - Diffuse Large B Cell LymphomaOncologyJun 2027
NCT06504940OrelabrutinibPhase 2Marginal Zone LymphomaOncologyJul 2027
NCT06496308OrelabrutinibPhase 3Mantle Cell Lymphoma (MCL)OncologyJul 2027
NCT07022223OrelabrutinibPhase 2Marginal Zone Lymphoma(MZL)OncologySep 2027
NCT06583837OrelabrutinibPhase 2Lymphoma, B-Cell, Marginal ZoneOncologySep 2027
NCT07355699OrelabrutinibPhase 4Marginal Zone Lymphoma(MZL)OncologySep 2027
NCT06700798OrelabrutinibPhase 2Marginal Zone Lymphoma(MZL)OncologyDec 2027
NCT07082686ICP-248Phase 2Relapsed or Refractory Mantle Cell Lymphoma (MCL)OncologyDec 2027
NCT07441993OrelabrutinibPhase 2Marginal Zone LymphomaOncologyDec 2027
NCT05745623ICP-723Phase 1Advanced Solid Tumors Harboring NTRK FusionOncologyDec 2027
NCT07247383OrelabrutinibPhase 2Marginal Zone Lymphoma of Ocular AdnexalOncologyDec 2027
NCT05600660OrelabrutinibPhase 2Primary Central Nervous System LymphomaOncologyDec 2027
NCT06985472OrelabrutinibPhase 2Initial MZLOncologyDec 2027
NCT07499271OrelabrutinibPhase 2Diffuse Large B-Cell Lymphoma (DLBCL)OncologyDec 2027
NCT07448324OrelabrutinibPhase 2Marginal Zone Lymphoma(MZL)OncologyJan 2028
NCT06228963OrelabrutinibPhase 2MALT Lymphoma of StomachOncologyJan 2028
NCT04685226ICP-723Phase 1Solid TumorsOncologyJan 2028
NCT07554898OrelabrutinibPhase 2MALT LymphomaOncologyFeb 2028
NCT07372365OrelabrutinibPhase 2Marginal Zone Lymphoma (MZL)OncologyApr 2028
NCT06454968OrelabrutinibPhase 2Marginal Zone LymphomaOncologyJun 2028
NCT07208981OrelabrutinibPhase 2Marginal Zone Lymphoma(MZL)OncologyJun 2028
NCT07199296OrelabrutinibPhase 2Mantle Cell Lymphoma (MCL)OncologyJul 2028
NCT06566807OrelabrutinibPhase 2Marginal Zone LymphomaOncologyAug 2028
NCT04989621OrelabrutinibPhase 2Follicular LymphomaOncologyAug 2028
NCT06082102OrelabrutinibPhase 3Relapsed/Refractory Marginal Zone LymphomaOncologyAug 2028
NCT07272499OrelabrutinibPhase 2Mantle Cell Lymphoma (MCL)OncologySep 2028
NCT07378527ICP-332Phase 2Chronic Spontaneous Urticaria (CSU)ImmunologySep 2028
NCT06521255LenalidomidePhase 3DLBCLOncologySep 2028
NCT07185373OrelabrutinibPhase 2Primary Central Nervous System LymphomaOncologySep 2028
NCT06503276OrelabrutinibPhase 2Extranodal Marginal Zone B-cell LymphomaOncologyOct 2028
NCT06793189OrelabrutinibPhase 2Marginal Zone Lymphoma(MZL)OncologyDec 2028
NCT07410520OrelabrutinibPhase 2Primary Central Nervous System Lymphoma (PCNSL)OncologyDec 2028
NCT07078500OrelabrutinibPhase 2Diffuse Large B-Cell Lymphoma (DLBCL)OncologyDec 2028
NCT07047612ICP-332Phase 2Non Segmental VitiligoImmunologyApr 2029
NCT07719556OrelabrutinibPhase 2Mantle Cell Lymphoma (MCL)OncologyJul 2029
NCT06378138ICP-248Phase 2Hematologic MalignanciesOncologyNov 2030
NCT06378138OrelabrutinibPhase 2Hematologic MalignanciesOncologyNov 2030
NCT07617493ICP-B208Phase 1Advanced Solid TumorOncologyDec 2030

Targets

BTK (1) FYN (1) FGFR2 (1) CRBN (1) DDB1 (1) CUL4A (1) RBX1 (1)

Companies with the same targets

Bristol-Myers Squibb Roche BeOne Medicines Incyte Shandong New Time Pharmaceutical CellCentric AstraZeneca Sanofi Eli Lilly Johnson & Johnson (Janssen)

Companies built like this

Jiangsu Hansoh Pharmaceutical Incyte Akeso Dizal Pharmaceuticals Taiho Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.